In short
Clinical trials are studying Melphalan Hydrochloride in different cancers, including adult Philadelphia chromosome-positive acute lymphoblastic leukemia and retinoblastoma. These studies look at how well treatment works, how safe and effective it is, and what outcomes matter most for patients, such as survival, eye preservation, and visual function.
Key points
- Clinical trials involving Melphalan Hydrochloride are studying two different cancer settings: adult Philadelphia chromosome-positive acute lymphoblastic leukemia and retinoblastoma. The leukemia study is Phase 3 and compares a treatment strategy against chemotherapy with Imatinib in adults, with event-free survival as the main outcome. The retinoblastoma study is Phase 2 and looks at eye-preserving treatment approaches. Its main outcomes are eye preservation and visual function. Together, these trials show that Melphalan Hydrochloride is being studied as part of broader treatment plans rather than alone.
Trial overview
The trial data shows two interventional studies that include Melphalan Hydrochloride as part of the treatment plan. One study is in adult Philadelphia chromosome-positive acute lymphoblastic leukemia, and the other is in ocular conservative treatment for retinoblastoma. Both studies are authorised.
Adult Ph+ ALL study
NCT04722848 is a Phase 3 study in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, also written as Ph+ ALL. The study title says it is testing whether a sequence based on Ponatinib plus Blinatumomab works better than chemotherapy with Imatinib. Melphalan Hydrochloride is listed among the drugs used in the chemotherapy part of the trial.
The study includes adults aged 18 years and older, with no upper age limit. The brief summary says the trial is looking at a front-line chemo-free strategy with Ponatinib plus steroids for induction, followed by Blinatumomab for consolidation, and comparing it with a chemotherapy scheme combined with Imatinib. In simple terms, the researchers want to know which treatment path gives better results for newly treated adults with this leukemia.
Retinoblastoma study
NCT04681417 is a Phase 2 study of conservative treatment for retinoblastoma, which is an eye cancer. The study looks at the effectiveness of new management strategies and visual outcome. Melphalan Hydrochloride is listed in the investigational arm and in the reference arm as part of eye-directed treatment.
The brief summary says Study 1 evaluates local control of the disease in patients eligible for intra-arterial chemotherapy, often shortened to IAC. Study 2 looks at visual function in patients eligible for other conservative treatments, including intravenous chemotherapy with local eye treatments or local treatment without intravenous chemotherapy. This means the trial is focused on saving the eye and keeping vision as good as possible.
Main outcomes and endpoints
The leukemia trial uses event-free survival, or EFS, as the primary endpoint. The trial defines events as not reaching MRD negativity, death from any cause, toxicity, and resistance, including resistance linked to ABL1 mutation development. MRD negativity means no measurable minimal residual disease, which is the very small amount of cancer that may remain after treatment.
The retinoblastoma trial has two main outcomes. The first is eye preservation 24 months after randomization in the investigational and reference arms. The second is the percentage of patients with major, mild, or no visual impairment according to WHO criteria when the child reaches 6 years of age and has at least 24 months of follow-up.
Who can participate
The leukemia study is for adults with Ph+ ALL, and the source states there is no upper age limit. The retinoblastoma study is for patients eligible for conservative eye treatment, including those who can receive intra-arterial chemotherapy or other eye-sparing approaches. These are different patient groups, so the trial goals are also different.
Trial phases and study design
NCT04722848 is an interventional Phase 3 trial with 236 planned participants. Phase 3 studies usually compare treatment strategies in larger groups to see which works better. NCT04681417 is an interventional Phase 2 trial with 225 planned participants. Phase 2 studies usually focus more closely on how well a treatment works and on key patient outcomes.
In the leukemia study, the design is a comparison between a Ponatinib plus Blinatumomab strategy and a chemotherapy plus Imatinib strategy. In the retinoblastoma study, the design includes an investigational arm and a reference arm, with one part of the study being randomized. These designs help researchers compare outcomes in a fair way.